For the first time, researchers have identified that an immune cell subset called gamma delta T cells may be causing and/or perpetuating the systemic inflammation found with normal aging among the general geriatric population and in HIV-infected people who are responding well to drugs (anti-retrovirals).
Even with effective viral control, HIV-infected individuals are at a higher risk for diseases associated with older age than the general population. Unfortunately, the cell subsets driving inflammation in HIV infection and with normal aging are not yet understood. Also, whether antiretroviral therapy (ART) suppressed HIV infection causes premature induction of the inflammatory events found in uninfected elderly or if a novel inflammatory network ensues when HIV and older age co-exist is unclear.
To understand the cellular network that drives the onset and progression of age-associated morbidities in both ART-suppressed HIV and healthy aging, researchers from BUSM conducted a study that measured many markers on the surface of immune cells in the blood of people either with or without HIV that were sub-divided into two groups: younger (less than 35 years) and older (over 50 years) and compared that data with levels of inflammatory proteins in their plasma. This unique group of patients was recruited for the study by co-last author Nina Lin, MD, Assistant Professor of Medicine at BUSM and an infectious disease clinician at Boston Medical Center.
Researchers found that a marker on gamma delta T cells, called TIGIT, tracked significantly with plasma inflammatory markers in both the HIV+ and uninfected subject groups, and therefore could be targeted to potentially stop this ‘inflamm-aging’ found in both HIV+ people and the general geriatric population.
“Our study indicates that a previously uninvestigated immune cell subset in the setting of chronic inflammation with aging or HIV infection, gamma delta T cells, could be causing and/or perpetuating many illnesses in the elderly and in individuals with HIV. Therefore, we believe that targeted gamma delta T cell therapeutics could lead to reduced onset, symptoms, and/or severity of inflammation-related diseases,” explained corresponding author Jennifer Snyder-Cappione, PhD, Assistant Professor of Microbiology and Director of the Flow Cytometry Core Facility at BUSM.
More than 50 percent of the HIV-infected population in the U.S. is older than 50 years and the world’s geriatric population over the ages of 65 and 80 is predicted to double and nearly quadruple, respectively, by 2050. “Revealing and then therapeutically targeting the cell populations and precise immune networks that drive ‘inflamm-aging’ both with and without HIV infection is a preeminent global health priority,” added Dr. Snyder-Cappione.
The researchers, which include first author Anna Belkina, MD, PhD, Assistant Professor of Pathology and Laboratory Medicine at BUSM, hope that their study will spur new investigation and clinical trials targeting gamma delta T cell subsets to control unchecked inflammation and thereby reduce the onset and progression of many chronic diseases.
The Latest on: Chronic inflammation
via Google News
The Latest on: Chronic inflammation
- Regen BioPharma, Inc. Examines Combining Cannabidiol (CBD) With Its Lead NR2F6 Agonist To Treat for Inflammatory Bowel Disease on January 8, 2019 at 5:39 am
IBD is a disease caused by persistent and chronic inflammation of the gastrointestinal tract and is a term that refers to both ulcerative colitis and Crohn's disease. Current treatments include non-sp... […]
- Speaker: Better foods can battle chronic diseases on January 7, 2019 at 7:30 pm
MOLINE - Chronic diseases are not only preventable ... The acid breaks down into prostaglandins, which causes increased inflammation and pain, according to Bryant's research. […]
- Cellular energy route finding may improve understanding of aging, chronic disease on January 7, 2019 at 1:41 pm
The body loses its ability to manufacture NAD over time. At the same time, it seems to begin burning more NAD, likely due to chronic inflammation. If we can give NMN and aid its transport into cells, ... […]
- Chronic Pain Treatment Market to Reach $105.9 Billion by 2024: P&S Intelligence on January 6, 2019 at 9:45 pm
The category of drugs is further classified into opioids, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants, and other drugs. Opioids dominate the chronic pain drugs mar... […]
- New podcast: Barbara Olendzki on gut health and chronic pain on January 6, 2019 at 9:09 pm
Olendzki has been conducting research to understand why specific foods can alleviate symptoms of inflammatory bowel disease, a chronic inflammatory condition of the intestinal tract that can cause deb... […]
- Corvidia Therapeutics to Present on Novel Anti-Inflammatory Therapy for Cardio-Renal Disease at J.P. Morgan Healthcare Conference on January 4, 2019 at 3:56 pm
Inflammation has been established as a causal factor in the residual risk of cardiovascular patients, particularly within the context of chronic kidney disease, with a susceptible population of ... […]
- Living Well: Essential oils useful to help alleviate inflammation, pain on January 4, 2019 at 11:14 am
While a certain amount of inflammation is helpful in fighting an injured or infected area, too much or chronic inflammation can be problematic. Essential oils, such as lavender and peppermint, can hel... […]
- Living Well: Proper nutrition can break inflammatory cycle on January 4, 2019 at 11:13 am
It is chronic inflammation. While traditional medicine primarily focuses on managing diseases pharmaceutically, in functional health care, we seek to uncover and address the sources of inflammation in ... […]
- Rising incidences of chronic inflammatory and autoimmune diseases has increased the need of anti-inflammatory therapeutics Market on January 3, 2019 at 11:26 am
According to a new report published by apacmarket.com, titled, Anti-inflammatory Therapeutics Asia-Pacific Market Research Report, 2014-2020, the Asia-Pacific anti-inflammatory therapeutics market is ... […]
- Persistent fatigue induced by interferon-alpha: a novel, inflammation-based, proxy model of chronic fatigue syndrome on December 31, 2018 at 3:20 pm
The role of immune or infective triggers in the pathogenesis of Chronic Fatigue Syndrome (CFS) is not yet fully understood. Barriers to obtaining immune measures at baseline (i.e., before the trigger) ... […]
via Bing News